Annual report pursuant to Section 13 and 15(d)

Acquisition - Schedule of Allocation of Purchase Price (Details)

Acquisition - Schedule of Allocation of Purchase Price (Details) - USD ($)			1 Months Ended	2 Months Ended	3 Months Ended	7 Months Ended	10 Months Ended	12 Months Ended
	Feb. 16, 2018	Nov. 17, 2017	Dec. 31, 2017	Mar. 31, 2018	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2016
Fair value of liabilities assumed:
Debt assumed in Avadel Pediatric Products acquisition			$ 0					$ (15,075,000)
Goodwill			14,292,282					16,411,123	$ 0
Measurement Period Adjustments
Intangible assets								1,527,998
Goodwill								$ (1,659,160)
Avadel
Business Acquisition [Line Items]
Inventory	$ 718,000
Prepaid expenses and other current assets	570,000
Identifiable Intangible Assets:
Intangible assets	18,291,000
Fair value of liabilities assumed:
Accrued expenses and other current liabilities	(362,000)
Debt assumed in Avadel Pediatric Products acquisition	(15,075,000)
Fair value of contingent consideration	(7,920,000)
Total identifiable net assets	(3,778,000)
Fair value of consideration transferred	1
Goodwill	3,778,001
Measurement Period Adjustments
Inventory				$ 300,000	$ (1,831,000)
Prepaid assets					570,000
Intangible assets					1,838,000	$ 1,838,000
Accrued expenses					(362,000)
Fair value of debt assumed					197,303
Fair value of contingent consideration					(44,835)
Total net liabilities assumed					367,468
Consideration exchanged					(240,999)
Goodwill					$ (608,467)
TRx
Business Acquisition [Line Items]
Fair value of assets acquired:		$ 11,068
Accounts receivable, net		2,872,545
Inventory		495,777
Prepaid expenses and other current assets		134,281
Other receivables		2,764,515
Identifiable Intangible Assets:
Intangible assets		19,596,000
Total assets acquired		25,874,186
Fair value of liabilities assumed:
Accounts payable		192,706
Accrued expenses and other current liabilities		(8,614,937)
Deferred tax liability		918,613
Total liabilities assumed		9,726,256
Total identifiable net assets		16,147,930
Fair value of consideration transferred		28,781,052
Goodwill		12,633,122
Measurement Period Adjustments
Accounts receivable, net							$ 0
Inventory			$ 200,000				0
Prepaid assets							0
Other receivables							2,764,515
Intangible assets							1,528,000
Total assets acquired							4,292,515
Accounts payable							0
Accrued expenses							(3,764,515)
Deferred tax liability							78,840
Fair value of contingent consideration							1,210,000
Total liabilities assumed							3,843,355
Total net liabilities assumed							449,160
Consideration exchanged							(1,210,000)
Goodwill							(1,659,160)
PAI Sales & Marketing Agreement \| TRx
Identifiable Intangible Assets:
Intangible assets		2,553,000
Measurement Period Adjustments
Intangible assets							219,000
Metafolin \| Acquired Product Marketing Rights \| TRx
Identifiable Intangible Assets:
Intangible assets		11,987,000
Measurement Period Adjustments
Intangible assets							1,522,000
Millipred \| Acquired Product Marketing Rights \| TRx
Identifiable Intangible Assets:
Intangible assets		5,056,000
Measurement Period Adjustments
Intangible assets							342,000
Ulesfia \| Acquired Product Marketing Rights \| TRx
Identifiable Intangible Assets:
Intangible assets		0
Measurement Period Adjustments
Intangible assets							$ (555,000)
Previously Reported \| Avadel
Business Acquisition [Line Items]
Inventory	2,549,000
Prepaid expenses and other current assets	0
Identifiable Intangible Assets:
Intangible assets	16,453,000
Fair value of liabilities assumed:
Accrued expenses and other current liabilities	0
Debt assumed in Avadel Pediatric Products acquisition	(15,272,303)
Fair value of contingent consideration	(7,875,165)
Total identifiable net assets	(4,145,468)
Fair value of consideration transferred	241,000
Goodwill	$ 4,386,468
Previously Reported \| TRx
Business Acquisition [Line Items]
Fair value of assets acquired:		11,068
Accounts receivable, net		2,872,545
Inventory		495,777
Prepaid expenses and other current assets		134,281
Other receivables		0
Identifiable Intangible Assets:
Intangible assets		18,068,000
Total assets acquired		21,581,671
Fair value of liabilities assumed:
Accounts payable		192,706
Accrued expenses and other current liabilities		(4,850,422)
Deferred tax liability		839,773
Total liabilities assumed		5,882,901
Total identifiable net assets		15,698,770
Fair value of consideration transferred		29,991,052
Goodwill		14,292,282
Previously Reported \| PAI Sales & Marketing Agreement \| TRx
Identifiable Intangible Assets:
Intangible assets		2,334,000
Previously Reported \| Metafolin \| Acquired Product Marketing Rights \| TRx
Identifiable Intangible Assets:
Intangible assets		10,465,000
Previously Reported \| Millipred \| Acquired Product Marketing Rights \| TRx
Identifiable Intangible Assets:
Intangible assets		4,714,000
Previously Reported \| Ulesfia \| Acquired Product Marketing Rights \| TRx
Identifiable Intangible Assets:
Intangible assets		$ 555,000